Meet Our Team

Dr. Adam de la Zerda is the Founder and CEO of Visby Medical. Dr. de la Zerda is also an Associate Professor at Stanford University School of Medicine. In 2012, he became the youngest tenure track faculty at Stanford Medical School. He has experience in basic and translational research in molecular diagnostics, with biomedical engineering training during his PhD studies at Stanford University, chemistry and biochemistry postdoctoral training at University of California at Berkeley, and electrical engineering, computer science and physics training in his undergraduate studies at the Technion – Israel Institute of Technology. He has received over 20 honors and awards including Forbes Magazine 30-under-30 in Science and Healthcare in 2013 and 2014, Chan-Zuckerberg Investigator from Facebook Founder and CEO Mark Zuckerberg, DP5 Early Independence Award from the Director of the NIH, and he recently gave a popular TED Talk.

Dr. Schoolnik is Chief Medical Officer, Visby Medical. He is also Professor of Medicine (emeritus), Stanford Medical School, Attending Physician in Internal Medicine and Infectious Diseases at Stanford University Hospital and Associate Director of Stanford’s Institute for Immunology, Transplantation and Infection. Dr. Schoolnik received his M.D. degree and infectious diseases subspecialty training at the University of Washington in Seattle, served as medical intern, resident and chief resident at Harvard’s Massachusetts General Hospital in Boston and he was a research associate and associate physician at the Rockefeller University in Manhattan. While on the Stanford Medical School faculty he served as Chief of the Division of Infectious Diseases and Geographic Medicine. National service included his appointment to the Advisory Council of the National Institutes of Allergy and Infectious Diseases of the NIH and his role as chair of the NIH Trans-Institute Committee on the Human Microbiome and co-chair of the NIH Blue Ribbon Committee on Bioterrorism. International consultative activities include the Board of Scientific Counselors of Fudan University in Shanghai. He was founding editor of the journal Molecular Microbiology and Associate Editor of the Journal of Clinical Investigation. His academic research focuses on the molecular, genetic and genomic aspects of infectious agents and on the development of new drugs, vaccines and diagnostics. Gary has 6 issued patents.

Scott Verner was Chairman, CEO and President of TRIVIDIA Health, a leading developer and manufacturer of diabetes management solutions and blood glucose monitoring systems, formed in the merger of Nipro Diagnostics Inc. and assets of Sinocare, Inc. Before TRIVIDIA Health, Scott served as Chairman , President, and Group CEO of Nipro Diagnostics, Inc. and Chairman of two other affiliated businesses (Nipro Health Care and Applied Sciences Corporation).

 

Over the last 10 years, Scott has built shareholder value and created equity events for three public companies in the global consumer healthcare, medical device, and pharmaceutical industries. He possesses strong financial acumen, expertise in fund raising and restructuring debt, and operations experience with public companies, private equity, venture capital, and IPOs. Scott has an extensive record of achievement growing companies and brands, leading turnarounds, building world class sales and marketing capabilities, launching new products, and restructuring sales and marketing operations.

Beth has over 25 years of experience in leadership roles in Quality, Regulatory, Clinical, and Scientific Affairs for molecular in vitro diagnostic companies. She has extensive experience working in highly entrepreneurial environments and has been responsible for starting several new departments for companies that are in the process of establishing businesses in the IVD space. This includes implementation of a robust quality system at Myriad Genetics (a CLIA and New York State certified laboratory specializing in resequencing to determine cancer risk) and starting the Quality, Regulatory and Clinical Affairs Departments at Idaho Technology (now known as BioFire Diagnostics) a highly successful IVD and biotechnology company. While leading Regulatory and Clinical Affairs at BioFire, we obtained FDA clearances and CE marking for 3 molecular syndromic infectious disease tests with review times that were consistently less than the 90-day review period. Beth holds a MS in clinical laboratory science from the University of Illinois at Chicago and enjoys being outside hiking, biking, skiing or playing tennis.

Mark is a career operations, engineering and supply chain executive with more than 34 years of experience. He has held leadership roles at several industry leading companies including Abbott Labs, Flextronics, Harry’s, Texas Instruments, Micron, and JUUL. Mark has managed a number of technology manufacturing operations around the world, producing a diverse array of products including medical devices, consumer electronics, industrial products, network equipment, razors and semiconductor fabrication equipment. Additionally, Mark was a founding partner of Riverwood Solutions, an outsourced operations management services and consulting company providing a broad range of services for leading start-ups and Fortune 500 companies. He has advised and actively managed well over 100 new product introductions, product transfers, and product development and industrialization programs in the U.S., Europe, Mexico and Asia. Mark has a BS in Materials Engineering from Purdue University and has eleven U.S. patents. He has occasionally guest lectured on design for supply chain, outsourced manufacturing and supply chain management at the University of Texas in Austin.

Dr. Roy has 16 years experience developing complex biomolecular systems in the Life Science and In Vitro Diagnostics industries. He was the eighth employee hired at Geneweave Biosciences, where he eventually went on to become the head of engineering and develop an instrument and cartridge platform for the detection of infectious disease. Geneweave was acquired by Roche Molecular Systems in 2015. Prior to Geneweave, Shaunak was a Senior Process Engineer at Complete Genomics, where he worked on what was at the time, the world’s fastest DNA sequencer. Complete Genomics went IPO in 2010 and was acquired by BGI in 2012. At Visby, Shaunak leads our Research and Development organization and is responsible for all aspects of product development, from high level concept and feasibility work to launch of new assays and platforms. He holds a BS in Chemical Engineering from Northwestern University and a PhD in chemical engineering from Stanford University. He is an author on four published papers and twenty two issued patents.

Mr. Meyer has over 30 years of leadership experience in Silicon Valley finance and accounting. He’s helped several public and late-stage private companies develop strategic plans and implement tactical growth and restructuring plans. He’s led multiple public offerings and buyside and sellside transactions of up to $600 million. Prior to joining Visby, Bill provided strategic and tactical financial consulting services to leading Silicon Valley companies in various industries, including medical diagnostics. Previously, he held Chief Financial Officer and other senior finance roles at Bell Microproducts, Broadvision, inSilicon, Phoenix Technologies and Arthur Andersen. He received his BS degree from California State University, Sacramento, and is a CPA in the state of California (inactive).

Carrie O’Brien has over 17 years of experience in Human Resources across organizational design, executive coaching, compensation and benefits, and change management expertise. Most recently she served as the Director of Compensation at Schneider National. Carrie brings experience working in different industries, with proven success in driving outcomes that support and enable business growth.